Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes
Executive Summary
Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.
You may also be interested in...
US Chief Trent Takes Helm Of Irish Medtech Atlantic Therapeutics
Susan Trent joined the subsidiary of Bio-Medical Research Ltd. in 2019 as senior VP and US general manager to market Innovo.. She'd previously worked with GlaxoSmithKline for more than 20 years and as an industry consultant.
OTC Incontinence Device Ad Claims Sunk In UK, But US Label Claims Have FDA OK
UK ASA upholds complaints that questioned claims made in 2018 TV ads that Innovo was clinically proven to strengthen the pelvic floor and treat bladder weakness. In the US, however, claims Atlantic Therapeutics will use to promote OTC sales of Innovo were approved by FDA.
Global Device Approvals, Weekly Snapshot: Pelvic Floor Strengthener, Peripheral Stent
A snapshot of medical device approvals captured in Medtech Insight's Approvals Tracker. A muscle stimulation device to treat urinary incontinence passed US FDA's review, while a peripheral artery stent with a new delivery system gained European sign off.